Project Grant R01CA301558
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $664K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- The National Cancer Institute awarded the University of Pittsburgh $638,422 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define the impact of detachment sensing proteins in ovarian cancer metastasis. The research identifies and characterizes genes and signaling pathways essential to peritoneal metastasis in high-grade serous ovarian adenocarcinoma, focusing on RHOV, an atypical GTPase that functions as a novel TGF-β/SMAD signaling integrator. The project uses in...
- The National Cancer Institute awarded the University of Pittsburgh $638,771 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate non-canonical functions of the mitochondrial fission protein DRP1 in high-grade serous ovarian cancer. Research will examine how a DRP1 splice variant (DRP1−/17) redistributes from mitochondria to microtubules and centrosomes, driving tumor proliferation, metastasis, and chemoresistance through localized centrosome protein synthesis...
- The National Cancer Institute awarded the University of Pittsburgh $408,829 on June 12, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and refine a high-throughput single-cell morphological analysis pipeline for identifying and targeting polyploid giant cancer cells (PGCCs) in breast cancer treatment resistance. The recipient will improve the robustness and accuracy of its preliminary single-cell analysis pipeline across diverse staining and imaging...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $621,121 on July 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tumor-niche co-evolution mechanisms driving ovarian cancer metastasis and therapeutic resistance. The research integrates clonal barcoding, single-cell RNA sequencing, and in vivo CRISPR screens to trace the evolutionary trajectory of metastatic ovarian cancer cells and define niche adaptive changes that...
- The National Cancer Institute awarded the Research Institute At Nationwide Children's Hospital $146,779 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate metastatic tumor microenvironmental mechanisms in osteosarcoma and develop novel therapeutic approaches. The funded research identifies mechanisms underlying metastatic establishment in osteosarcoma by examining interactions between epithelial cells, macrophages, and tumor cells within the...
- The National Cancer Institute awarded the University of Pittsburgh $649,620 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine Medicare Advantage plan impacts on cancer care access, quality, and outcomes for older adults. The project investigates whether Medicare Advantage's limited provider networks create barriers to timely specialty care for patients with the four most prevalent cancers—breast, colorectal, lung, and prostate. The research employs...
- The National Cancer Institute awarded the University of Pittsburgh $164,190 on January 21, 2026, under the Cancer Research Manpower program (CFDA 93.398) to conduct computational and wet lab research on metastatic breast cancer genomics and tumor evolution tracking. The project applies machine learning and phylogeny analysis tools—including transformer models—to identify recurrent patterns of gene deletions in metastatic breast cancer samples. The work integrates genomic data from the AURORA...
- The National Institutes of Health National Cancer Institute awarded the University of Pittsburgh $577,662 on August 5, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to study genomic and epigenomic signatures in alternative lengthening of telomeres (ALT) cancers. The award funds investigation of centromeric repeat insertions and centromere protein-A nucleosome formation at telomeres in cancer cells that activate the ALT pathway. The research hypothesizes that these...
- The National Cancer Institute awarded the University of Pittsburgh $261,662 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct an integrated in silico and in vivo genetic screening study identifying subtype-specific hepatocellular carcinoma genetic dependencies. The research combines computational deep-learning prediction of genetic dependencies with in vivo loss-of-function screening in murine hepatocellular carcinoma models representing the Hoshida...
- The National Cancer Institute awarded the University of Pittsburgh $408,829 on May 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate lipogenesis-mediated resistance to cytotoxic therapy in pancreatic ductal adenocarcinoma. The research characterizes how tumor cells upregulate de novo lipid production following chemotherapy and radiation therapy to escape ferroptosis-induced cell death and evade immune-mediated killing through M2 macrophage polarization. The...